top of page

Trial Enrollment

PRISM
Prism supports clinical trial enrollment by matching patients to trials or trials to patients.

THE PROBLEM

Oncologists and their staff are collectively responsible for matching thousands of patients to hundreds of clinical trials each year. This complex, computationally intensive task is ideally suited for artificial intelligence (AI), yet the methodologies have not changed for decades. Due to the lack of a scalable process for clinicians and their staff to match patients with trials, the task often requires manual chart reviews. Consequently, some patients fall through the cracks and miss out on potentially life-altering treatments.

Oncologists and clinical trial coordinators must match 1,000s of patients to 100s of clinical trials.

UNDERSTANDING PRISM

Watch our VP of Clinical Data, Regina Schwind, as she introduces Prism, our trial enrollment solution, and explains how we collaborate with various organizations.

HOW IT WORKS

Powered by OncoLLM, Prism can manage various approaches and challenges related to clinical trial enrollment. The platform is designed to help match patients with trials and vice versa, among other capabilities:

OUR RESULTS

We measured the performance of our platform in accurately identifying trials for patients at a cancer center with hundreds of ongoing oncology trials. Our system achieved an accuracy of over 95% in identifying the correct trial within its top three recommendations, accomplishing this in just minutes. You can learn more at this link.

Prism achieved over 95% accuracy in identifying the correct clinical trial in its top 3 recommendations.

WE DESIGNED OUR PLATFORM TO BE

Proactive

The system continually tracks upcoming or recent appointments and radiology results, and provides an in-basket notification to the clinician and study team when a match is found.

Comprehensive

Prism works across your entire portfolio, including federally funded, investigator-initiated, and industry-sponsored trials.

Compatible

We integrate with existing EHRs, including Epic, Cerner, OncoEMR and more, and are approved and available on Epic's app marketplace.

Scalable

Prism doesn't require complex, study-specific builds, letting you go-live with all your studies on Day 0.

Accurate

Our published data shows that our models outperform larger language models and traditional NLP solutions. 

Accessible and Equitable

At-scale prescreening of patients from underserved communities enables research teams to meet their diversity enrollment targets, increasing cancer trial access and equity.

Patient-to-Trial Matching

Screen patients with upcoming appointments for all locally ongoing trials.

Patient-to-Trial Matching: Screen patients with upcoming appointments for all locally ongoing trials.
Image by National Cancer Institute

CONTACT US

601 Montgomery St, Suite 1100
San Francisco, CA 94111

EMAIL

partnerships@triomics.com

Copyright 2024

Proactive

The system continually tracks upcoming or recent appointments and radiology results, and provides an in-basket notification to the clinician and study team when a match is found.

Compatible

We integrate with existing EHRs, including Epic, Cerner, OncoEMR and several others,and are approved and available on Epic's app marketplace.

Accurate

Our published data shows that our models outperform larger language models and traditional NLP solutions.

Comprehensive

Ability to utilize Prism across your entire portfolio, including federally funded, investigator initiated and sponsor led trials.

Scalable

Prism doesn't require complex, study-specific builds, letting you go-live with all your studies on Day 0

More Accessible and Equitable

At-scale pre-screening of patients from under-served communities enables the research teams to meet their diversity enrolment targets, increasing access and equity in cancer trials.

OUR SOLUTION

We designed our platform to be:

WHY PRISM

Trial sponsors benefit from recruitment of more patients, in less time, from larger and more diverse catchment areas. Plus, our process can be supported by an expert-led team of clinical navigators.
bottom of page